Robert Maki, MD
Hematology & Oncology · Philadelphia, PANPI 1538130323
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,941 of the $55,650 with a category attached, or 86.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 19.8%. Reporting peaked in 2023 at $18,320 and has fallen 99.3% since, to $136 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $1294.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- Deciphera Pharmaceuticals Inc.$11K
- Boehringer Ingelheim International GmbH$9K
- Daiichi Sankyo Inc.$6K
- Bayer$5K
- Ipsen Bioscience Inc.$3K
- plus $11K from 9 others
Across 87 payments — averaging $15,527 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$472K
- Otsuka Pharmaceutical Co., Ltd.$260K
- Pfizer$237K
- Regeneron$148K
- Merck$96K
- Day One Biopharmaceuticals$74K
- plus $65K from 6 others
What the payments were for
- Consulting fees$47,94186%
- Speaking & faculty fees$6,52012%
- Travel & lodging$4791%
- Food & beverage$7101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $10,991 |
| Deciphera Pharmaceuticals Inc. | 3 | $10,548 |
| Boehringer Ingelheim International GmbH | 9 | $9,115 |
| Daiichi Sankyo Inc. | 7 | $6,330 |
| Bayer | 5 | $4,632 |
| Ipsen Bioscience Inc. | 1 | $3,480 |
| Ipsen Biopharmaceuticals, Inc | 1 | $3,020 |
| Amgen | 1 | $2,596 |
| GSK | 2 | $2,046 |
| Medtronic | 1 | $1,200 |
| Bavarian Nordic A/s | 1 | $800 |
| Pfizer | 1 | $780 |
| Exelixis Inc. | 1 | $41 |
| Geron Corporation | 1 | $40 |
| Genentech, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,650 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 27 | $403,400 |
| Imatinib Mesylate | 82 | $166,636 |
| Sunitinib Malate | 11 | $63,361 |
| Ondansetron Hcl | 24 | $290 |
| Oxycodone Hcl | 17 | $203 |
| Sodium Chloride0.9 % Sodium Chloride | 11 | $198 |
| Dexamethasone | 12 | $129 |
| Amlodipine Besylate | 11 | $87 |
| Levothyroxine Sodium | 12 | $77 |
| Gabapentin | 12 | $61 |
| Tamsulosin Hcl | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $780 | $403,40027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.